CERAMIC
An Observational Study of the Role of Antibiotics, Inflammation and Changes in Microbiota in the Development of Post-infective Bowel Dysfunction Following Infection With Campylobacter Jejuni or Coli
Sponsor study identifier
Secondary identifiers
OTHER · National Research Ethics Committee
observational
450
1 country
1
Study Start
January 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2017
Actual (reported)Study Completion
June 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The principal research objective is to determine the impact of antibiotic use on the risk of developing long term bowel symptoms after infection with the germ Campylobacter.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2013
Date type not reportedThis date has not been verified as actual or estimated.
January 14, 2014
Actual (reported)January 20, 2014
Actual (reported)February 2017
Actual (reported)June 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Yes/ no: Post-Infective bowel dysfunction (PI-BD)
This will be defined by response to the question "have your bowels returned to normal since your Campylobacter infection?"
12 weeks after microbiological diagnosis of infection
Yes/ No: Post-Infective irritable bowel syndrome (PI-IBS)
12 weeks after microbiological diagnosis of infection
Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured
Adults in the Nottinghamshire area with no previous history of gastrointestinal disorder or surgical resection. Those who submit a stoo lsample from which Campylobacter spp. is cultured will be invited to take part.
University of Nottingham
Nottingham, NG7 2UH, United Kingdom
Jalanka J, Gunn D, Singh G, Krishnasamy S, Lingaya M, Crispie F, Finnegan L, Cotter P, James L, Nowak A, Major G, Spiller RC. Postinfective bowel dysfunction following Campylobacter enteritis is characterised by reduced microbiota diversity and impaired microbiota recovery. Gut. 2023 Mar;72(3):451-459. doi: 10.1136/gutjnl-2021-326828. Epub 2022 Sep 28.
Stool (Faeces) Whole Blood
Robin C Spiller, MSc MD FRCP
University of Nottingham
Giles AD Major, BM BCh MRCP
University of Nottingham
Mathew Diggle, MSc PhD
Nottingham University Hospitals NHS Trust
Richard Puleston, MBBS PhD
University of Nottingham
First Submitted
January 14, 2014
First Posted
January 20, 2014
Study Start
January 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2017
Actual (reported)Carbohydrate Reduction and Impact on Gastrointestinal System
Contact the study team to confirm eligibility.
Miranda Lomer, PhD RD
King's College London
Study Completion
June 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 4, 2017
Record last verified: 2017-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: